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Abstract
Vaccines against S. pneumoniae, one of the most prevalent bacterial infections causing severe disease, rely on isolated capsular
polysaccharide (CPS) that are conjugated to proteins. Such isolates contain a heterogeneous oligosaccharide mixture of different
chain lengths and frame shifts. Access to defined synthetic S. pneumoniae CPS structures is desirable. Known syntheses of S. pneu-
moniae serotype 3 CPS rely on a time-consuming and low-yielding late-stage oxidation step, or use disaccharide building blocks
which limits variability. Herein, we report the first iterative automated glycan assembly (AGA) of a conjugation-ready S. pneu-
moniae serotype 3 CPS trisaccharide. This oligosaccharide was assembled using a novel glucuronic acid building block to circum-
vent the need for a late-stage oxidation. The introduction of a washing step with the activator prior to each glycosylation cycle
greatly increased the yields by neutralizing any residual base from deprotection steps in the synthetic cycle. This process improve-
ment is applicable to AGA of many other oligosaccharides.
Introduction
The Gram-positive encapsulated commensal bacterium Strepto-
coccus pneumoniae [1-3] can cause serious medical conditions
like pneumonia, meningitis, endocarditis and sepsis [4].
S. pneumoniae is the leading cause of vaccine-preventable
deaths in children under five years worldwide [5]. Over 90 dif-
ferent serotypes of S. pneumoniae have been identified, each of
which expresses a unique capsular polysaccharide (CPS) [6-9].
The S. pneumoniae serotype 3 CPS was first isolated in 1924
[10] and its exact chemical structure was finally elucidated in
1941 [11], as being composed of repeating units of β-(1,3)-
linked cellobiuronic acid (Figure 1).
CPS plays a major role in S. pneumoniae virulence [12]. A
commercial 17-valent polysaccharide vaccine was introduced in
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Figure 2: Building blocks and solid support for the automated solid-phase synthesis of S. pneumoniae serotype 3 CPS structures.
Figure 1: Disaccharide repeating unit of the S. pneumoniae serotype 3
CPS.
1977, followed by a 23-valent vaccine in 1983 [13-15].
Serotype 3 of S. pneumoniae is one of the most prevalent
serotypes causing acute otitis media [16] and is one of the thir-
teen serotypes included in the blockbuster pneumococcal conju-
gate vaccine Prevnar 13® [17,18].
Vaccines against S. pneumoniae are usually manufactured using
isolated CPS structures containing oligosaccharides of different
lengths and frame shifts [19]. Synthetic oligosaccharide anti-
gens enable structure–activity relationship (SAR) studies of
bacterial antigens [20] to better understand antibody binding
and help to improve existing vaccine formulations.
Two synthetic routes to prepare serotype 3 oligosaccharides
have been developed and were applied to other uronic acid con-
taining carbohydrate structures [21,22]. The first method uses
only glucose building blocks to assemble oligosaccharides and
introduces the C6 carboxylic acid moieties via a late-stage oxi-
dation. Using this method, serotype 3 di-, tri- and tetrasaccha-
rides were synthesized [23]. The other approach directly uses
glucuronic acid building blocks as glycosylating agents. Due to
the electron-withdrawing C6 carboxyl group, uronic acids ex-
hibit a decreased reactivity both as glycosylating agents and
as nucleophiles. Disaccharide building blocks containing
glucuronic acid were used by de Jong et al. to prepare two dif-
ferent SP 3 trisaccharides [24]. In general, the late-stage-oxida-
tion approach is often preferred since it circumvents the
inherent reactivity issues associated with uronic acid building
blocks [25-27].
Automated glycan assembly builds on monomeric building
blocks that are incorporated during iterative glycosylations
[28,29]. Here, a set of building blocks was identified that can be
employed interchangeably in the automated syntheses of a wide
variety of biologically relevant glycans. To minimize the post-
automation chemical modifications and the loss of product, we
assembled pneumococcal serotype 3 CPS structures utilizing
glucose and glucuronic acid monosaccharide building blocks
and thus avoided late-stage oxidations.
Results and Discussion
Mindful of this strategic framework, glucuronic acid building
block 1 was designed (Figure 2). A levulinoyl (Lev) ester was
chosen as temporary protecting group (TPG) since the Fmoc
(fluorenylmethoxycarbonyl) group led to a loss of stereocontrol
during glycosylations with this glucuronic acid (GlcA) building
block (data not shown). Glucose building blocks 2 and 3 were
equipped with two benzyl ethers to account for the low reactivi-
ty of glucuronic acids as glycosylating agents and carried either
Fmoc or Lev groups. As solid support, we chose photolabile-
linker-functionalized Merrifield resin 4 for its compatibility
with the activation conditions for glycosyl phosphates, its mild
cleavage conditions and the possibility to directly conjugate the
product after global deprotection via the amine functional group
[28]. The presence of glucuronic acids in the oligosaccharide
sequence precludes the use of a base-labile linker due to the risk
of elimination reactions [30].
The building blocks were synthesized in high yields using stan-
dard protecting group chemistry (see Supporting Information
File 1). Solid support 4 was prepared according to an estab-
lished procedure [28].
The automated glycosylation protocol employed three times
three equivalents of building block to ensure complete glycosyl-
ation of the nucleophile (Scheme 1). The glycosyl phosphate
building blocks 1 and 2 were activated by stoichiometric
amounts of TMSOTf (trimethylsilyl trifluoromethanesulfonate)
at −30 °C and reacted at this temperature for 30 min. Then the
temperature was raised to −15 °C and maintained for 30 min.
The temporary Fmoc protecting group was cleaved with tri-
ethylamine in DMF (N,N-dimethylformamide; 10% v/v). The
Lev protecting group was removed using hydrazine monohy-
drate in pyridine/acetic acid (3:2 v/v).
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Scheme 1: Attempted assembly of SP3 trisaccharide 5 using glycosyl phosphate building blocks 1 and 2. Reagents and conditions: a) 2 (3 equiv),
TMSOTf, CH2Cl2, −30 °C (30 min) to −15 °C (30 min), n = 3; b) Et3N in DMF (10% v/v), 25 °C (15 min), n = 3; c) 1 (3 equiv), TMSOTf, CH2Cl2, −30 °C
(30 min) to −15 °C (30 min), n = 3; d) N2H4·H2O, pyridine/AcOH (3:2 v/v), CH2Cl2, 30 min, n = 3; e) hν.
Figure 3: HPLC chromatogram of the crude products of the attempted AGA of SP3 trisaccharide 5; conditions: YMC Diol 300, H/EtOAc, 0% EtOAc
(5 min) to 55% EtOAc (70 min), ELSD.
The crude oligosaccharide products were cleaved from the solid
support by irradiation with UV light in a flow reactor [28] and
analyzed by normal-phase HPLC (Figure 3).
Trisaccharide 6 lacking one C2-benzoate ester protecting group
was identified as the main product. The unexpected side reac-
tion was attributed to the basicity of the Fmoc deprotection
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Scheme 2: Attempted AGA of SP3 trisaccharide 9 using glycosyl phosphate building blocks 1 and 3. Reagents and conditions: a) 3 (3 equiv),
TMSOTf, CH2Cl2, −30 °C (30 min) to −15 °C (30 min), n = 3; b) N2H4·H2O, pyridine/AcOH (3:2 v/v), CH2Cl2, 30 min, n = 3; c) TMSOTf, CH2Cl2,
−30 °C (1 min), n = 1; d) 1 (3 equiv), TMSOTf, CH2Cl2, −30 °C (30 min) to −15 °C (30 min), n = 3; e) hν.
solution. In addition, two deletion sequences (7 and 8) were also
detected. Glycosylations mediated by the strongly acidic activa-
tor TMSOTf were found to be neutral when exiting the reaction
vessel. An incomplete removal of the strongly basic deprotec-
tion solutions would result in quenching of the next glycosyla-
tions. Indeed, test runs on the automated synthesis instrument
illustrated regular washing steps following each deprotection
failed to completely remove the deprotection solution. There-
fore, an activator wash step was introduced between deprotec-
tion and glycosylation steps. In this step, the resin was washed
with activator solution at −30 °C for one minute in order to neu-
tralize any residual base. Remaining traces of water that would
hydrolyze the glycosylating agent in the following glycosyla-
tion cycle are also effectively removed hereby. Furthermore,
Fmoc-protected glucose building block 2 was replaced with
Lev-protected 3. The use of the buffered hydrazine solution for
the cleavage of Lev TPGs was expected to prevent any unde-
sired benzoyl ester cleavage. The trisaccharide synthesis was
repeated using the same glycosylation conditions as in the
previous synthesis (Scheme 2).
After each glycosylation step, the pH of the glycosylation solu-
tions exiting the reaction chamber was tested and found to be
Figure 4: HPLC chromatogram of the crude products of the attempted
AGA of SP3 trisaccharide 9; conditions: YMC Diol 300, H/EtOAc, 0%
EtOAc (5 min) to 70% EtOAc (70 min), ELSD.
strongly acidic. After cleavage from the solid support, HPLC
analysis of the crude product showed one major product
(Figure 4). However, MALDI–TOF MS analysis indicated that
this fraction corresponded to a tetrasaccharide addition se-
quence, resulting from benzoyl ester cleavage and a double
glycosylation in the last step (see Supporting Information
File 1). This result was not expected as the buffered hydrazine
deprotection protocol had never favored the formation of side
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Scheme 4: Automated synthesis of SP3 trisaccharide 5 using glycosyl phosphate building blocks 1 and 2. Reagents and conditions: a) 2 (3 equiv),
TMSOTf, CH2Cl2, −30 °C (30 min) to −15 °C (30 min), n = 3; b) Et3N in DMF (10% v/v), 25 °C (15 min), n = 3; c) TMSOTf, CH2Cl2, −30 °C (1 min),
n = 1; d) 1 (3 equiv), TMSOTf, CH2Cl2, −30 °C (30 min) to −15 °C (30 min), n = 3; e) N2H4·OAc, pyridine/AcOH (4:1 v/v), 40 °C, 10 min, n = 2; f) hν,
69% over 6 steps.
products in our hands. However, this finding also highlighted
the efficiency of glycosylating agent 3 that can effectively
glycosylate two free hydroxy groups in one step with nine
equivalents of glycosylating agent 3.
Different conditions for the cleavage of the Lev protecting
group on solid support had been developed previously [24,31].
Performing the reaction at elevated temperature (40 °C), it is
possible to use less hydrazine acetate (7.8 equivalents).
Adapting these conditions to the automated synthesizer, each
Lev deprotection was followed by an activator washing step. In
order to test the modified deprotection conditions, glucuronic
acid 1 was reacted with the linker, and the temporary Lev
protecting group was removed using the adapted deprotection
protocol (Scheme 3).
The HPLC analysis showed quantitative cleavage of the Lev
protecting group without loss of the benzoyl ester to afford 10
(not shown).
With this encouraging result in hand, the synthesis of S. pneu-
moniae serotype 3 CPS trisaccharide 5 was attempted utilizing
the new protocol for the removal of the Lev group (Scheme 4).
In order to minimize the number of Lev deprotection steps, we
Scheme 3: Automated synthesis of linker-bound glucuronic acid 10
using glycosyl phosphate building block 1. Reagents and conditions:
a) 1 (3 equiv), TMSOTf, CH2Cl2, −30 °C (30 min) to −15 °C (30 min),
n = 3; b) N2H4·OAc, pyridine/AcOH (4:1 v/v), 40 °C, 10 min, n = 2; c)
hν.
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Scheme 5: Global deprotection of SP3 trisaccharide 5. Reagents and conditions: a) LiOH, H2O2, THF, −5 °C to rt; b) NaOH, MeOH, 0 °C to rt;
c) Pd(OH)2/C, MeOH/H2O/AcOH (50:25:1 v/v/v), 71% over 3 steps.
returned to the initial strategy using Fmoc-protected glycosyl
phosphate 2 as the glucose building block. This monomer did
not suffer from a loss of stereocontrol as was observed in the
case of the similarly protected GlcA building block.
The desired trisaccharide 5 was observed as the main product
from the automated synthesis by HPLC analysis (Figure 5). The
Lev protecting group had been removed quantitatively while no
benzoyl ester cleavage was observed. None of the byproducts
could be identified by either ESIMS or NMR.
Figure 5: HPLC chromatogram of the crude products of the auto-
mated solid-phase SP3 trisaccharide 5 synthesis; conditions: YMC Diol
300, H/EtOAc, 0% EtOAc (5 min) to 60% EtOAc (60 min), 254 nm.
The S. pneumoniae serotype 3 trisaccharide 5 was isolated in
69% yield and deprotected in three steps. First, the methyl ester
was removed under mild conditions using a mixture of lithium
hydroxide and hydrogen peroxide to avoid elimination reac-
tions which are common for uronic acid methyl esters under
strongly basic conditions [30,32]. In the next step, the
remaining esters were removed employing sodium hydroxide in
methanol. Finally, catalytic hydrogenation using Pd(OH)2/C in
methanol/water/acetic acid (50:25:1 v/v/v) afforded the fully
deprotected S. pneumoniae serotype 3 CPS antigen 11 in 71%
yield over three steps (Scheme 5).
Conclusion
The first automated glycan assembly of a conjugation-ready
S. pneumoniae serotype 3 trisaccharide 11 using glucuronic acid
building blocks was achieved. The need for a late-stage oxida-
tion was circumvented by using a novel glucuronic acid build-
ing block, thereby shortening the synthetic route by two steps.
Selective C6-OH deprotection/oxidation steps on oligosaccha-
rides are usually not very efficient (53% over two steps for a tri-
saccharide), and are characterized by decreasing yields with in-
creasing chain length [23]. The GlcA building block proved to
be an efficient glycosylating agent, that is expected to serve
well in the synthesis of other oligosaccharide antigens. Libera-
tion of the C3-OH group of glucuronic acid 1 for chain elonga-
tion proved delicate. Standard hydrazine cleavage conditions for
the Lev protecting group also removed a benzoyl ester and lead
to the formation of unwanted products. Using hydrazine acetate
at slightly elevated temperatures (40 °C) [24,31] cleaved the
levulinoyl groups on mono- and trisaccharides while retaining
all benzoyl esters. The introduction of an activator washing step
prior to each glycosylation greatly increased the reproducibility
of the automated syntheses and is envisioned to increase effi-
cacy of AGA for many other biologically relevant glycans in
the future.
In conclusion, we have developed an efficient method for the
synthesis of S. pneumoniae serotype 3 CPS structures. The
products of these syntheses are currently used in the develop-
ment of synthetic carbohydrate conjugate vaccines.
Supporting Information
Supporting Information File 1
Experimental details as well as full characterization of all
new compounds.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-12-139-S1.pdf]
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